Research & Development

World-class scholar in metabolic area

Johan Auwerx Director (Registered), HSC

• Professor at Swiss Federal Institute of Technology Lausanne (EPFL)
• Member of European Molecular Biology Organization (EMBO)
• Editorial member of international academic journals (Cell, Science, etc.)
• MD, Ph.D. in Molecular Endocrinology, Katholieke Universiteit Leuven

Metabolic area and brain disease research core expert

Hoe-Yune Jung Each Representative, Research Director

• Adjunct Professor of System Biotechnology at Pohang University of Science & Technology
• Lifetime member of the Korean Diabetes Association
• MS in Life Science, Handong Global University
• Ph.D. in Convergence Biotechnology, Pohang University of Science & Technology

Kyong-Tai Kim, PhD

Dr. Kim is an experienced brain disease researcher and has served as a board member of NovMetaPharma, since February 2016. Since March 2023, he has also been serving concurrently as a Distinguished Professor at Handong Global University. From August 2019 to July 2021, he led the Research Division at the POSCO Research Institute of Science and Technology. He was a professor and later head professor at the Department of Life Sciences at POSTECH (Pohang University of Science and Technology) from July 1991 until February 2023. Between March 2010 and August 2002, he also served as a director of the Brain Research Center at POSTECH. Dr. Kim earned his Ph.D. in Molecular and Cell Biology from the University of Massachusetts, completing his studies from September 1985 to February 1989.

Obesity research expert

Frank Greenway SA

• Professor at Pennington Biomedical Research Center (PBRC)
• Clinical Trials Unit Core at PBRC, Chief Medical Officer
• (Former) metabolic disease specialist, Harbor-UCLA Medical Center
• University of California, Los Angeles MD

Bong Youl Chung, PhD

Dr. Chung has served as a leading expert in pegylation technology at NovMetaPharma, since September 2019. Prior to this, he was a professor in the Department of Chemistry and Medicinal Chemistry at Yonsei University from July 2007 to August 2019. From September 2011 to June 2017, he also served as a chief technology officer and president at Huons Co., Ltd. (HuMedix), where he successfully led the company to a KOSDAQ listing in 2014. Before that, he was CTO and President at Pheromone Co., Ltd. (PherAon) from May 2008 to August 2011. Earlier in his career, he held the position of vice president at Chemizon Co., Ltd. from September 2006 to November 2007, where he contributed to the company’s public listing. He also led R&D efforts as a head of technology research at SDC Co., Ltd. (July 2005 – August 2006), and as a director of the Central Research Center at UK Chemipharm (November 2003 – October 2004). From January 1996 to October 2003, he served as a director of the Animal Pharmaceutical Research Institute at LG Life Sciences. Mr. Chung earned his Ph.D. from the University of Maine in December 1995.